News

Deal Announcements

Armetheon Arms With Series B Venture Capital

Friday, February 6, 2015 5:33:00 AM PDT | VentureDeal
   Santa Clara, California  --  Biopharmaceutical company Armetheon has secured $24.3 million in its second round of venture capital investment.

Armetheonis developing "novel drugs for highly unmet need in cardiovascular diseases."

The investor syndicate included Capital TEN II, CDIB, iD SoftCapital Group, AmKey Ventures and others.

The company said it would use the funding to advance its lead clinical candidate, tecafarin that it says avoid adverse drug reactions associated with warfarin.

Armetheon previously raised $7 million in its first round of financing in August 2014.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1